Exelixis (EXEL)
(Delayed Data from NSDQ)
$22.40 USD
-0.15 (-0.67%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $22.41 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Company Summary
Alameda, CA-based Exelixis, Inc. is an oncology-focused biotechnology company that primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company is leveraging its investments, expertise and strategic partnerships to target an expanding range of tumor types and indications with its clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs) and other biotherapeutics.
Currently, the company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the company’s flagship molecule, which is an inhibitor of multiple tyrosine kinases, including MET, ...
Company Summary
Alameda, CA-based Exelixis, Inc. is an oncology-focused biotechnology company that primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company is leveraging its investments, expertise and strategic partnerships to target an expanding range of tumor types and indications with its clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs) and other biotherapeutics.
Currently, the company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the company’s flagship molecule, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET. Cabometyx (cabozantinib) tablets are approved for advanced RCC both alone and in combination with Opdivo. It is also approved for previously treated HCC. The drug was also approved for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cometriq (cabozantinib) capsules are approved for progressive, metastatic medullary thyroid cancer (MTC); Cotellic (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat advanced melanoma, is marketed under a collaboration with Roche’s Genentech, Inc. and Minnebro (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited.
Exelixis has a licensing agreement with Ipsen whereby Ipsen has exclusive commercialization rights for current and potential future indications of cabozantinib outside the United States and Japan. The company also has granted Takeda the right to develop and commercialize cabozantinib in Japan. The company also has collaborated with other leading pharmaceutical and biotechnology companies, such as Bristol-Myers, for various compounds and programs in its portfolio.
The company is also trying to build its pipeline through its drug discovery efforts. Important candidates in its pipeline include zanzalintinib, a next-generation oral tyrosine kinase inhibitor (TKI) and XB002, an ADC that targets tissue factor (TF).
The company earns revenues through milestones and royalty payments from these collaborations. Revenues in 2023 came in at $1.8 billion, up from 14% in 2022.
General Information
Exelixis, Inc
1851 Harbor Bay Parkway
Alameda, CA 94502
Phone: 650-837-7000
Fax: 650-837-8300
Email: shubbard@exelixis.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 8/6/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.37 |
Current Year EPS Consensus Estimate | 1.39 |
Estimated Long-Term EPS Growth Rate | 35.30 |
Exp Earnings Date | 8/6/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 22.55 |
52 Week High | 24.34 |
52 Week Low | 18.64 |
Beta | 0.54 |
20 Day Moving Average | 1,464,263.75 |
Target Price Consensus | 27.16 |
4 Week | 2.69 |
12 Week | 0.27 |
YTD | -6.00 |
4 Week | -0.09 |
12 Week | -10.03 |
YTD | -19.72 |
Shares Outstanding (millions) | 303.20 |
Market Capitalization (millions) | 6,837.16 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 16.24 |
Trailing 12 Months | 24.78 |
PEG Ratio | 0.46 |
vs. Previous Year | 0.00% |
vs. Previous Quarter | -55.56% |
vs. Previous Year | 4.02% |
vs. Previous Quarter | -11.35% |
Price/Book | 3.09 |
Price/Cash Flow | 29.28 |
Price / Sales | 3.70 |
6/30/24 | NA |
3/31/24 | 8.85 |
12/31/23 | 8.57 |
6/30/24 | NA |
3/31/24 | 6.91 |
12/31/23 | 6.81 |
6/30/24 | NA |
3/31/24 | 3.46 |
12/31/23 | 3.34 |
6/30/24 | NA |
3/31/24 | 3.41 |
12/31/23 | 3.30 |
6/30/24 | NA |
3/31/24 | 11.10 |
12/31/23 | 11.35 |
6/30/24 | NA |
3/31/24 | 11.10 |
12/31/23 | 11.35 |
6/30/24 | NA |
3/31/24 | 14.00 |
12/31/23 | 14.07 |
6/30/24 | NA |
3/31/24 | 7.31 |
12/31/23 | 7.47 |
6/30/24 | NA |
3/31/24 | 3.45 |
12/31/23 | 2.88 |
6/30/24 | NA |
3/31/24 | 0.00 |
12/31/23 | 0.00 |
6/30/24 | NA |
3/31/24 | 0.00 |
12/31/23 | 0.00 |